Key result
Expanding universal pediatric lipid screening to include lipoprotein (a) can serve as an effective strategy to uncover undiagnosed ASCVD in adult relatives through reverse cascade screening.
Answers are grounded in this paper and cite their sources.
Expanding universal pediatric lipid screening to include lipoprotein (a) is proposed as a strategy to identify high-risk youth and their adult relatives for ASCVD prevention through reverse cascade screening.
Pediatric lipid screening remains underutilized, despite recommendations from many professional societies. In particular, certain lipid disorders such as familial hypercholesterolemia and elevated lipoprotein (a) are highly heritable and detectable in childhood. This low uptake represents not only a missed opportunity to identify high-risk youth for atherosclerotic cardiovascular disease (ASCVD), but also a lost occasion to identify high-risk adult relatives through reverse cascade screening. Expanding universal pediatric lipid screening to include lipoprotein (a) can serve as an effective strategy to uncover undiagnosed ASCVD in their relatives. Early identification of affected, asymptomatic individuals could prevent ASCVD morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Hyman et al. (2026) conducted an editorial in Lipid disorders and atherosclerotic cardiovascular disease (ASCVD). Universal pediatric lipid screening including lipoprotein (a) was evaluated. Expanding universal pediatric lipid screening to include lipoprotein (a) can serve as an effective strategy to uncover undiagnosed ASCVD in adult relatives through reverse cascade screening.
Synapse has enriched 10 related papers. Consider them for comparative context: